Limitations of angiotensin inhibition

Nature Reviews Nephrology

Volumn 7, Issue 6, 2011, Pages 356-359

  Nobakht, Niloofar ^a   Kamgar, Mohammad ^a   Rastogi, Anjay ^a   Schrier, Robert W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATHEPSIN G; CHYMASE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRORENIN; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MONOTHERAPY; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECOND MESSENGER; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 85027946136     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.29     Document Type: Review

References (29)

1. Gerstein, H. C. et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 19, 1225-1228 (1996).
2. McPherson, E. A. et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 15, 493-500 (2004).
3. Chapman, A. B., Johnson, A., Gabow, P. A. & Schrier, R. W. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1091-1096 (1990).
4. Loghman-Adham, M., Soto, C. E., Inagami, T. & Cassis, L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 287, 755-768 (2004).
5. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
6. Brenner, B. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
7. Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993).
8. Wolf, G. & Ritz, E. Combinatin therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 67, 799-812 (2005).
9. Nakao, N. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361, 117-124 (2003). Retraction in: Lancet 374, 1226 (2009).
10. Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003).
11. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
12. Cohn, J. N. et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valslartan Heart Failure Trial. Circulation 108, 1306-1309 (2003).
13. Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
14. Staessen, J., Lijnen, P., Fagard, R., Verschueren, L. J. & Amery, A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 91, 457-465 (1981).
15. Bomback, A. S. & Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486-492 (2007).
16. Schjoedt, K. J., Anderson, S., Rossing, P., Tarnow, L. & Parving, H. H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47, 1936-1939 (2004).
17. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N. Engl. J. Med. 341, 709-717 (1999).
18. Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L. & Mukherjee, R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118, 1643-1650 (2008).
19. Schrier, R. W., Masoumi, A. & Elhassan, E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin. J. Am. Soc. Nephrol. 5, 1132-1140 (2010).
20. Schrier, R. W. Aldosterone 'escape' vs 'breakthrough.' Nat. Rev. Nephrol. 6, 61 (2010).
21. Battenburg, W. W. & Jan Danser, A. H. The (pro)renin receptor: a new addition to the renin-angiotensin system? Eur. J. Pharmacol. 585, 320-324 (2008).
22. Lindenmeyer, M. T. et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J. Am. Soc. Nephrol. 18, 1765-1776 (2007).
23. Kang, J. J. et al. The collecting duct is the major source of prorenin in diabetes. Hypertension 51, 1597-1604 (2008).
24. Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
25. Riccioni, O., Vitulano, N., D'Orazio, N. & Bellocci, F. Aliskiren, the first approved renin inhibitor: clinical application and safety in the treatment of hypertension. Adv. Ther. 26, 700-710 (2009).
26. Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
27. Parving, H. H. et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663-1671 (2009).
28. McMurray, J. J. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
29. Sanoski, C. A. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 29, 193-212 (2009).